The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Viridian Therapeutics Inc shares valued at $117,050 were purchased by Beetham Thomas W. on Sep 27 ’24. At $23.41 per share, Beetham Thomas W. acquired 5,000 shares. The insider’s holdings grew to 6,000 shares worth approximately $0.11 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Mahoney Stephen F. purchased 21,400 shares, netting a total of over 499,262 in proceeds. Following the buying of shares at $23.33 each, the insider now holds 21,400 shares.
Before that, Fairmount Funds Management LLC had added 1,600,000 shares to its account. In a trade valued at $30,000,000, the Director bought Viridian Therapeutics Inc shares for $18.75 each. Upon closing the transaction, the insider’s holdings increased to 1,600,000 shares, worth approximately $61.99 million.
As published in their initiating research note from TD Cowen on November 25, 2024, Viridian Therapeutics Inc [VRDN] has been a Buy. Analysts at Needham resumed the stock at ‘”a Buy”‘ outlook in a report released in mid September. As of June 11, 2024, Wolfe Research has initiated its “an Outperform” rating for VRDN. Earlier on June 06, 2024, Goldman initiated its rating. Their recommendation was “a Buy” for VRDN stock.
Analyzing VRDN Stock Performance
During the last five days, there has been a drop of approximately -8.35%. Over the course of the year, Viridian Therapeutics Inc shares have dropped approximately -17.40%. Shares of the company reached a 52-week high of $27.20 on 11/12/24 and a 52-week low of $11.40 on 06/04/24. A 50-day SMA is recorded $22.20, while a 200-day SMA reached $17.29. Nevertheless, trading volume fell to 1.3 million shares from 0.96 million shares the previous day.
Support And Resistance Levels for Viridian Therapeutics Inc (VRDN)
According to the 24-hour chart, there is a support level at 17.63, which, if violated, would cause prices to drop to 17.26. In the upper region, resistance lies at 18.69. The next price resistance is at 19.39. RSI (Relative Strength Index) is 29.52 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.43, which suggests the price will decrease in the coming days. Percent R is at 99.30%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
